The National Institutes of Health (NIH) intends to procure a one-year supply of Allo Seq Tx17 Next Generation Sequencing (NGS) reagent kits from CareDX Lab Solutions Inc. This acquisition will support the Human Leukocyte Antigen (HLA) Laboratory within the Department of Transfusion Medicine at the NIH Clinical Center in Bethesda, Maryland. The procurement is structured to include quarterly deliveries scheduled for February, May, and August 2026, ensuring the laboratory maintains an adequate stock of reagents for patient testing throughout the performance period, which runs from January 16, 2026, to September 30, 2026.

The HLA Laboratory plays a critical role in providing clinical diagnostic laboratory testing for patients at the Clinical Center, particularly in determining transplant eligibility and supporting enrollment in related clinical protocols. Additionally, the laboratory offers consultation services to Clinical Center physicians to assist with patient management in transplant scenarios. This steady supply of NGS reagent kits is essential to maintaining the laboratory's testing capabilities and supporting the NIH's mission in biomedical research and patient care.